Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Consolidated Net Income: 2023-2025

Historic Consolidated Net Income for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to -$60.1 million.

  • Immunome's Consolidated Net Income fell 19.03% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of -$305.8 million for FY2024, which is 179.19% down from last year.
  • As of Q3 2025, Immunome's Consolidated Net Income stood at -$60.1 million, which was down 29.39% from -$46.5 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Consolidated Net Income ranged from a high of -$4.5 million in Q1 2023 and a low of -$132.3 million during Q1 2024.
  • For the 3-year period, Immunome's Consolidated Net Income averaged around -$51.5 million, with its median value being -$46.5 million (2025).
  • In the last 5 years, Immunome's Consolidated Net Income slumped by 2,859.05% in 2024 and then skyrocketed by 66.26% in 2025.
  • Over the past 3 years, Immunome's Consolidated Net Income (Quarterly) stood at -$94.7 million in 2023, then climbed by 12.34% to -$83.0 million in 2024, then declined by 19.03% to -$60.1 million in 2025.
  • Its Consolidated Net Income was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.